Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics stockholders approve 2026 equity plan and elect eight directors

Neutral Impact 2 of 5 shareholder Written later

At its September 29, 2026 annual meeting, Pelthos Therapeutics stockholders approved a new 2026 Equity Incentive Plan that replaces the 2023 plan, and re-elected all eight director nominees. Stockholders also ratified Grant Thornton LLP as the auditor for fiscal 2026. The filing reports votes only and does not disclose financial results.

Key points

  • Stockholders approved the 2026 Equity Incentive Plan, effective immediately, with 2,698,543 for and 187,365 against.
  • All eight director nominees were elected to serve until the 2027 annual meeting.
  • Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
  • Quorum was met with 3,396,094 votes, or 70.0% of voting power as of the August 4, 2026 record date.

The filing

CompanyPelthos Therapeutics Inc. (PTHS)
Form8-K, current report
Filed with the SECOct 1, 2026, 5:15 PM ET
Accession number0001919246-26-000125

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.